Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. Management will present from 10:30 AM to 11:00 AM ET and is available for one-on-one meetings. Key products include SPR720, targeting non-tuberculous mycobacterial infections, and Tebipenem HBr, an investigational drug for complicated urinary tract infections (cUTI). Spero is also developing SPR206, an IV-administered candidate for multi-drug resistant Gram-negative infections. Investors can access the webcast through the Spero website after the event. The company focuses on addressing rare diseases and multi-drug resistant bacterial infections with promising therapies.
Spero Therapeutics (Nasdaq: SPRO) announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The presentations, both authored by RE Mendes, Ph.D., focus on the in vitro activity of SPR206 against bacterial infections, highlighting its potential against Enterobacterales and Pseudomonas aeruginosa isolates in Europe. These studies underscore Spero's commitment to addressing multi-drug resistant (MDR) infections and developing effective treatments. The research was sponsored by Spero and supported by the Office of the Assistant Secretary of Defense for Health Affairs. For more details, visit Spero's official site for key publications and presentations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of 95,000 restricted stock unit awards (RSUs) to four new employees as part of the 2019 Inducement Equity Incentive Plan. This decision, made on March 23, 2023, aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four annual installments starting April 3, 2024, contingent on the employees' continued employment. Spero Therapeutics focuses on developing treatments for rare diseases and multi-drug resistant infections, with ongoing projects such as SPR720 and tebipenem HBr.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the initiation of a Phase 2 trial for SPR720, targeting nontuberculous mycobacterial pulmonary disease (NTM-PD), with results expected in 1H 2024. The company secured a $66 million upfront payment through an exclusive license agreement with GSK for tebipenem HBr, alongside a $9 million equity investment. For 2022, Spero reported a net income of $26.8 million in Q4, and a full-year loss of $46.4 million, up from a loss of $89.8 million in 2021. Total revenues rose significantly to $53.5 million from $18.3 million, primarily driven by collaboration with GSK and Pfizer. Spero's cash position stood at $109.1 million as of December 31, 2022.
FAQ
What is the current stock price of Spero Therapeuti (SPRO)?
What is the market cap of Spero Therapeuti (SPRO)?
